Protokoly_diagnostiki_i_lechenia_zabolevany

< &

: 04-044

"$ &: " :

& ! :

1. " & " ;

2.& ;

3., " ;

4." " % .

' & & : 21 &

(: J44.0 G " " &% &

J44.1 G " " & "

J44.9 G " " & "

J44.8 @ " " " &

J45.8 !

J43.0 ! 6-J

J43.9 7 ( ) ( " )

) : < & (<)(/) -& & , $# % &

, , .

<)(/ - , $# &$ ". 7 " " ""

$ :

* :

" : , 3

" :

" .

5 :

1.# ;

2.# " ;

3.& .

, & , $# . ! & % , # % & . ! & % & G <J 3 ".

V 7 < "

G " & ( % . L % &;& "&$), " ($ " "% & G <J), ( $),( $# . , " , & )

" & :

1.# ;

2.# " ;

3._ % & (_D>J) - (FVC);

4.V 1 (_'1) - (FEV1);

5.B – " , & & .

" & & :

1." _'1/_D>J (FEV1/FVC);

2.< ;

3.& ;

4.B " ;

5.B " ;

6." ;

7.&$ ;

8.< " .

+ :

1.< " .

2.6 " .

3.? & .

4.6 % .

5.& : 6- ,

, -, ( ).

6.B ( ). ? :

( ,-

" , % & " (?G7) .

' # $ " - " " . + *20 ,& # 3 .

b2- ( * 50 , & ** 100 , 100 ) $&$ $ ( ).

' " G <J % " & b2- "& $# # & & $ b2-, & " . # $ % "" " . @ 3 & : ( * 20 + * 50 ).

# !

? ** 30 & %" & & .

? *100 , 200200 " && .

$ *

( !) G <J 3 & & - $# .

7 & " , &$# % & & & G <J, . J & 10-30%" & &. @ , " &" , $ &$ $: 20-30 / " 0,4-0,6 / ( ) " 3 &. + 10% % " _'1 " _'1, , 200 3 &$% & &$ & && .

> - ! " & &, " 3 & % & , & "$ !* 100 / .

! ! " & " 3 ,

" %& . #. + ,$ & " . 3 V &$.

" % 2 60 p . ., % SaO2 < 85% 6- & < 88% ." & (18 " ) " (2-5 ), . % & " $ - . @

% . + " " $ Streptococcus pneumonia, Haemophilus influenzae, Moraxella catarralis . ?* "$ " ", " " 3 . " " " 3 " 7-14 ." & in vitro & 3 3 ". + " & . ?& & .

" & :

1.*_ 5 .; 0,5 /10 V ;

2.**! & 100 / 3 &; 2 , 4 .; 20 ;

3.*B 100 3 &;

4.**; 100 , 200 , 300 .; 350 ;

5.**? 30 .; 15 /2 .; 15 /5 , 30 /5 ;

6.*? 2% 2 .; 100 , 200 .;

7.* 30 / .; 5 .

" & & :

1.; 1000 ;

2.*? 500 , 1000 .; 250 ; 500 .; 250 /5 &;

3.*? + 625 .; 600 , V .

/ , & :

1.PRODIGY Guidance - Chronic obstructive pulmonary diseaseLast revised in July 2005 www.prodigy.nhs.uk/guidance.asp?gt=COPD

2.ICSI Institute For Clinical, Systems Improvement, Health Care Guideline, Chronic Obstructive Pulmonary Disease, Fourth Edition December 2004, www.icsi.org

3.Chronic Obstructive Pulmonary Disease (COPD) Australian and New Zealand Management Guidelines and the COPD Handbook Version 1, November 2002

4.GOLD (Global Initiative for chronic Obstructive Lung Disease), National Institute For Health, National Heart, Lung And Blood Institute, 2004

5.). . ? , ?.+. , !.B. " +. . G & , ?.+. / ?. . L " , >.B. K G " . _& 6D, ; 9 8 1, 2001

* – , # (% % ) ** - " & , "$ &

< $

: 11-117

"$ &: " :

& ! :

1." ;

2.& ;

3.& / " , ;

4.% ! 7.

$ :

1." " ;

2." " , " & ;

3." " , " % ;

4." " , ;

5." " , & ;

6." " , 3 ;

7." " , ;

8. " " , & ;

9." " , ;

10." " , ;

11." " , " .

* :

1.;

2." ( , , " , % , .);

3.% &;

2.# ;

3.;

4.H)B " $ ;

:

1.& " ( , , " –/ );

2. " " + ( – );

3.$ - (LE-, ?+?, ?+ ?, - ?+ ?, " " , );

4.(- + );

5.IgA ( < % );

6.' ! ( +, - +);

7." !_ – .

" & :

1.# " " – / / -3 ;

2.# ;

3.B ;

4.< ;

5.) ;

6.6 & ;

7., " ;

8., , & , , ;

9.G ;

10.;

11.H)B " $ ;

12..

" & & :

1.< . " " & ;

2._ - ;

3._ (!3, !4) ;

4." !_ K ;

5.LE-, ?+?, ?+ ?, -?+ ?, " " , ;

6.?;

7.6 ' !;

8.-# " ;

9. H & " " " ;

10.7 ;

11.;

/ ) – & (– *, * 40 / ., * 5-10 / .), †-

$# ( * 2-3 / / , * 0,2-0,3 / / )," ( * 2-3 / , * - 66_ 1-2 / ), *? 5-6 / / .

' , " & & – & .# " # &$:

-$# " $ « & »* 20-30 / / * 15-20 / / 1 $ " 3-4 &.

-&- – * ?

& " *

-$ - – * 8-12 &, %$# " 66_ *.

-- – " "( ' !), œ-, *.

% & " ( ) – "$# " * *. -

1 &$ & " * (40-60 /2 / 48 " )

? ¨¨ ( *, * .).

! ( *, *)

@ "$ & , $, ?@, , $.

+ @ % " :

1.& * 0,5-2,0;

2..@3* – 2-5 . 6>;

3.*1,0-4,0;

4.;

5.*;

6..

" & :

1.*_ 40 , .; 20 /2 ;

2.* 25 , .;

3.*! 25-50 ;

4.*7 2,5 , 10 , .; 1,25 /1 .;

5.* 5 , .; 30 / .;

6.*/ 50 , % ; 200 , 500 ,V ;

7.*G 250 , .; 500 .; 1000 ,V ;

8.*/ ? 25 , 100 , .;

9.*6 4 , 16 , .; 40 / , 80 /2 ,V .

" & & :

1. *_ 80 , .; 2.* @ 40 , .;

3.*' 40 , 80 , .;

4.*? 5 , 10 , .;

5.* $ & 500 , .; 100 /10 , ., V ;

6.' @3 10 ; 10 ;

7.*G 0,5-1,0 ;

8.* 30 / , V ;

9.*? & 5%, 10%, 20% ;

10.*? 50 .

/ , & :

1.K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002 Feb;39(2 Suppl 1):S1-246.

2.Haematuria EBM Guidelines 26.8.2004

3.Glomerulonephritis CLINICAL PRACTICE GUIDELINES MOH Clinical Practice Guidelines 6/2001 http://www.gov.sg/moh/pub/cpg/cpg.htm

4.Hematuria. Philadelphia (PA): Intracorp; 2005. Various p.

5.Singapore Ministry of Health. Glomerulonephritis. Singapore: Singapore Ministry of Health; 2001 Oct. 132 p

6.Glomerulonephritis EBM Guidelines 19.6.2004

* – , # (% % )